Judge Rules Pfizer's Lyrica Patents Are Valid
U.S. District Judge Gregory M. Sleet ruled that Pfizer and Northwestern University's three patents for Lyrica were not obvious, anticipated or invalid for any other reason, and issued an injunction banning Teva, Mylan and others from marketing no-name versions of the drug before it expires in 2018.
Lyrica, which was designed to...
Already a subscriber? Click here to login